In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $2.28.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Xencor, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 3.0% and a 35.87% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $13.40 average price target.
See Insiders’ Hot Stocks on TipRanks >>
STRO market cap is currently $139M and has a P/E ratio of -0.78.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sutro Biopharma (STRO) Company Description:
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
Read More on STRO:
- Vaxcyte in manufacturing pact with Sutro Biopharma for PCV franchise control
- Sutro Biopharma promotes Jane Chung to President and COO
- Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
- Sutro Biopharma price target lowered to $12 from $18 at Piper Sandler
- Sutro Biopharma files $300M mixed securities shelf
